| P50 | author | Yeon-Mok Oh | Q56532532 |
| | Kwang Ha Yoo | Q85265642 |
| | Ki-Suck Jung | Q85360203 |
| P2093 | author name string | Yong Chul Lee | |
| | Jae Jeong Shim | |
| | Chul-Gyu Yoo | |
| | Jeong-Woong Park | |
| | Seong Yong Lim | |
| | Young-Sam Kim | |
| | Song Kim | |
| | Hyoung-Kyu Yoon | |
| | Cheong-Ju Kim | |
| | Myung-Jae Park | |
| P2860 | cites work | Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America | Q56783663 |
| | Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. | Q64907436 |
| | Obstructive airways disease in patients with significant post- tuberculous lung scarring | Q80941704 |
| | Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study | Q21257191 |
| | Global burden of COPD: systematic review and meta-analysis | Q22299203 |
| | Effect of inhaled tiotropium on spirometric parameters in patients with tuberculous destroyed lung | Q28397030 |
| | COPD and the risk of tuberculosis--a population-based cohort study | Q28752596 |
| | The role of tuberculosis in COPD | Q29248960 |
| | Thoracic sequelae and complications of tuberculosis | Q34307916 |
| | Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease | Q37457359 |
| | Efficacy of indacaterol in the treatment of patients with COPD. | Q37904769 |
| | Tuberculosis and chronic respiratory disease: a systematic review. | Q38391408 |
| | Clinical characteristics of patients with tuberculosis-destroyed lung | Q38455569 |
| | Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis | Q39399389 |
| | Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium | Q42170464 |
| | Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease | Q43193974 |
| | Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. | Q45746909 |
| | Chronic obstructive airways disease following treated pulmonary tuberculosis | Q46731552 |
| | Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study | Q48315330 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 1589-1596 | |
| P577 | publication date | 2017-05-29 | |
| P1433 | published in | International Journal of Chronic Obstructive Pulmonary Disease | Q6051335 |
| P1476 | title | Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study | |
| P478 | volume | 12 | |